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Objective: In this study, we delivered ephrin-B2 to the ischemic hind limb of rabbits using an ex vivo method of gene
transfer and evaluated whether the in vivo application of ephrin-B2 contributed to the development of functional
collateral vessels. Ephrin-B2 is a transmembrane ligand of several Eph receptors and bidirectional signaling between
ephrin-B2 and Eph-B4 is considered to be essential in angiogenesis and the development of arteries and veins.
Method: The left femoral artery of male Japanese White rabbits was excised to induce limb ischemia, and a primary culture
of autofibroblasts was obtained from a skin section. Nineteen days later, the gene expressing ephrin-B2 (ephrin group) or
-galactosidase gene (control group) was adenovirally transfected to the cultured auto-fibroblasts (5 106 cells); then 48
hours later, the gene-transduced cells were injected through the left internal iliac artery of the same rabbit. At 28 days
after injection, the development of collateral vessels and their function were assessed (control group, n  12; ephrin
group, n  10).
Results: The gene expressing ephrin-B2 was successfully transferred to the rabbit autofibroblasts, and ephrin-B2,
expressed on the cell membrane, possessed binding ability with its receptor, Eph-B4. Calf blood pressure ratio (control
group: 0.523 0.047 vs ephrin group: 0.658 0.049, P< .0001), angiographic score (0.344 0.091 vs 0.525 0.109,
P  .0006), in vivo blood flow of the left internal iliac artery (rest: 11.963  2.806 vs 17.202  3.622 mL/min, P 
.0014; maximum: 27.652  10.377 vs 43.400  7.108 mL/min, P  .0007), collateral conductance (32.740  7.408
vs 54.489 18.809mL/min/100mmHg, P .0097), and capillary density of the left thighmuscle (118.517 18.669
vs 167.400  31.271, P  .0002) showed significant improvement in the ephrin-B2 group compared with controls.
Conclusion: These findings suggest that auto-fibroblasts expressing ephrin-B2 potentially promote arteriogenesis as well
as angiogenesis in the adult vasculature, resulting in the development of functional collateral vessels to an ischemic lesion.
(J Vasc Surg 2009;49:192-8.)
Clinical Relevance: Therapeutic enhancement of collateral vessel development is a promising strategy for the treatment of
vascular occlusive disease. We previously presented a new method for gene transfer of basic fibroblast growth factor and
showed excellent collateral development in animal models of limb ischemia andmyocardial ischemia. In the present study,
we delivered ephrin-B2 by using our therapeutic strategy and determined whether in vivo gene transfection with ephrin-B2
induces collateral development in animal model. It would suggest that ephrin-B2 provides potential for therapeutic
angiogenesis.Induction of angiogenic reactions to enhance collateral
vessel development is a promising approach for the treat-
ment of vascular occlusive diseases.1 Apart from particular
cases in which an ischemic lesion is caused only by micro-
vascular changes, a certain volume of the capillary bed is
preserved even in ischemic tissue.2 The principal goal of
angiogenic therapy is to supply sufficient blood flow to the
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192peripheral vascular bed pre-existing in the ischemic tissue.3
Collateral arteries, therefore, should possess reasonable
conduction ability and close connections with sufficient
blood inflow.2,4,5
To acquire conduction ability, collateral arteries need
to have sufficient size and a mature wall structure, suggest-
ing that the most desirable angiogenic process in this
therapy is arteriogenesis, that is, the process of vessel mat-
uration and enlargement.3,4 Connections with the blood
inflowmight be formed by promoting angiogenic reactions
between the adjacent artery with ample blood inflow (do-
nor artery) and the vascular bed in the ischemic tissue,
indicating that the ideal target of this therapy is the periph-
eral site of the donor artery.6
We previously presented a new therapeutic strategy to
achieve pinpoint delivery of an angiogenic growth factor to
the peripheral vascular network of the donor artery, in
which autofibroblasts, adenovirally transduced with an an-
giogenic growth factor gene, were selectively injected into the
donor artery for blood inflow (ex vivomethod).7-10 Because the
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were mechanically trapped in peripheral small vessels of the
donor artery after injection and released the growth factor
for a certain period. In our previous studies, the gene
expressing basic fibroblast growth factor (bFGF), a potent
promoter of arteriogenesis,3,11 was delivered by an ex vivo
method in animal models of limb7,9,10 and myocardial
ischemia,8 and favorable development of functional collat-
eral vessels was augmented. Although the ex vivo method
might be rather complex for clinical treatment, this method
enables the delivery of membrane-bound ligands in the
native form because auto cells were used as a delivery
carrier, which might be a marked advantage compared with
other delivery methods.
Ephrin-B2 is a transmembrane ligand and is predomi-
nantly expressed on arterial endothelial cells and surround-
ing cells.12 Ephrin-B2 can interact with several classes
of Eph receptors, and the bidirectional signaling between
ephrin-B2 and Eph-B4 is considered to be essential in angio-
genesis and the development of arteries and veins.13-16
Although the details of the ephrin-B2–Eph receptor system
are thus far poorly understood, a recent study presented
some evidence that ephrin-B2 can also promote the recruit-
ment and proliferation of vascular smooth muscle cells,
suggesting an important role in arteriogenesis.17 In the
present study, we used an ex vivo model to deliver the gene
expressing ephrin-B2 and evaluated whether in vivo appli-
cation of ephrin-B2–expressing fibroblasts contributed to
the development of functional collateral vessels in a rabbit
model of hind limb ischemia.
METHODS
Adenovirus vectors. Replication-deficient recombinant
adenovirus vectors containing full lengths mouse ephrin-B2
complimentary DNA (cDNA)18 (AxCAmephrinB2) or Eph-
B4 cDNA19 (AxCAmEphB4) were constructed according
to the method described previously.10 The control vec-
tor was AxCALacZ, which varies from the Escherichia coli
LacZ cDNA in the same expression unit.10 Our previous
experiment of AxCALacZ transduction to rabbit fibro-
blasts at 20 plaque-forming units (PFU)/cell revealed
100% efficacy by X-gal staining.7
In vitro study. Cultured rabbit fibroblasts in 60-mm
dishes (passage 3) were infected with AxCAmephrinB2 at
20 PFU/cell in 1 mL of Dulbecco modified Eagle mini-
mum essential medium (DMEM, Sigma-Aldrich, St Louis,
Mo) with 2% fetal bovine serum (FBS). The cells were
incubated for 1 hour, washed twice with phosphate buff-
ered saline (PBS), and cultured in 3 mL of the same
medium. The cells were harvested at 3, 7, 14, 21, and 28
days after infection and lysed in lysis buffer. Another group
of cells that were not infected was used as the control.
Each cell lysate (10 g total protein) underwent West-
ern blot analysis using goat polyclonal antibody against
mouse ephrin-B2 (1:1000, R & D Systems, Minneapolis,
Minn). In addition, AxCAmEphB4-treated fibroblasts
were evaluated by Western blot analysis using goat poly-
clonal antibody against human Eph-B4 (1:500, Santa CruzBiotechnology Inc, Santa Cruz, Calif) in the same manner.
To confirm whether the expressed ephrin-B2 was properly
presented on the cell membrane and further determine the
ability of expressed ephrin-B2 to adhere to its receptor,
AxCAmephrinB2-treated rabbit fibroblasts (1 106) were
mixed with AxCAmEphB4-treated fibroblasts (1  106),
and whether the mixed cells aggregated after 30-minute
agitation was assessed. As the control for this experiment,
AxCALacZ-treated rabbit fibroblasts were added instead of
AxCAmEphB4-treated cells.
Animal model of chronic hind limb ischemia. We
used a rabbit model of hind limb ischemia to evaluate in
vivo angiogenic responses. All protocols followed the
Guide for Care and Use of Laboratory Animals (National
Institutes of Health publication No. 85-23, revised 1996).
Male Japanese White rabbits weighing 2.7 to 3.4 Kg
(Saitama Rabbitry, Tokyo, Japan) were anesthetized by an
intramuscular injection of a mixture of ketamine (50 mg/
Kg) and xylazine (2.5 mg/Kg), and the left femoral artery
was completely removed from its proximal origin to the
bifurcation formed by the saphenous and popliteal arter-
ies.7,9,10 Before the wound was closed, a 10- 10-mm skin
section was obtained for primary culture of fibroblasts.
Ex vivo gene transfer. Fibroblasts were cultured from
the resected skin and grown to confluence in DMEM with
10% FBS in 100-mm dishes. In the event that 5  106
fibroblasts could not be prepared by 19 days after femoral
artery excision, subsequent experiments were discontinued.
At day 19, 5  106 fibroblasts (passage 3) were infected in
vitro with AxCALacZ or AxCAmephrinB2 at 20 PFU/cell
and incubated for 48 hours (from day 19 to day 21). At day
21 after femoral artery excision, when a chronic state of
ischemia had been achieved in the experimental limbs,20 a
3F end-hole infusion catheter (Rapid Transit, Cordis, Mi-
ami Lakes, Fla) was introduced into the left common
carotid artery and positioned in the left internal iliac artery
under fluoroscopic guidance. In this model of limb isch-
emia, the donor artery to the ischemic limb is the internal
iliac artery of the operated-on side. After being washed
twice with PBS, the fibroblasts infected with AxCALacZ
(control group, n  12) or AxCAmEphrinB2 (ephrin
group, n 10) were suspended in 1.5 mLDMEMwith 2%
FBS, and injected as a bolus through the infusion cathe-
ter.7,9,10 A student helper randomly assigned animals to the
treatment group or control group of the experiments.
Calf blood pressure ratio. Calf blood pressure was
measured in both hind limbs with a Doppler probe, and the
calf blood pressure ratio was calculated as the ratio of left
systolic pressure to right systolic pressure.7 The calf pressure
ratio was measured at three time points under anesthesia:
immediately after femoral artery removal, and immediately
before and 28 days after administration of gene-transduced
fibroblasts.
Angiographic score and in vivo blood flow. Selective
angiography of the left internal iliac artery was done 28 days
after cell administration. A 3F end-hole catheter was intro-
duced into the left iliac artery through the carotid artery, and
the catheter tip was positioned at the level of themiddle of the
JOURNAL OF VASCULAR SURGERY
January 2009194 Katsu et alfirst sacral vertebra. After intra-arterial administration of nitro-
glycerin (0.25 mg, Kyowa Co, Tokyo, Japan), 5 mL of con-
trast medium (Iopamiron370, Schering, Berlin, Germany)
was injected at a rate of 1 mL/second, and an angiogram was
taken at 4 seconds after the start of injection. A grid overlay
consisting of 2.5-mm-diameter circles arranged in rows
spaced 5mm apart was placed over the angiogram at the level
of themedial thigh. The number of contrast-opacified arteries
crossing over circles (CART) and the total number of circles
encompassing the medial thigh (CTOTAL) area were counted,
and the angiographic score was calculated as CART/CTOTAL,
as described previously.7,21
Before angiography, a 0.014-inch Doppler guidewire
(EndoSonics, Rancho Cordova, Calif) was introduced
through the 3F catheter into the proximal part of the left
internal iliac artery. Average peak velocity (APV) was mea-
sured at rest, and maximum APV was determined after a
bolus injection of papaverine (2 mg) through the catheter.
The arterial diameter (d) at the site of the Doppler sample
volume was measured on the arteriogram, and blood flow
was calculated as ([d2/4]  0.5  APV).7
Collateral conductance. At 28 days after cell injec-
tion, collateral conductance was measured according to a
method described previously.10,22 Animals were intubated
through a tracheotomy and ventilated with room air. The
jugular vein was cannulated for continuous infusion of
lactated Ringer’s solution and occasional injections of pen-
tobarbital to maintain an appropriate level of anesthesia.
After heparinization with heparin (2000 U), the right
femoral artery was cannulated with a 24-guage polyethyl-
ene infusion catheter (0.5 mm inner diameter; Terumo,
Tokyo, Japan) for sampling of a microsphere reference, and
the left saphenous artery was also cannulated with a 24-
guage infusion catheter just above the ankle.
The infrarenal abdominal aorta was exposed, cut down,
and cannulated in proximal and distal directions with 14-
gauge catheters (1.73 mm inner diameter) that were con-
nected to a pump to maintain stable flow to the hind limbs;
blood withdrawn from the proximally directed catheter and
infused from the distally directed catheter. The proximal
pressure of collateral arteries was recorded through the
distally directed catheter in the aorta, and the left saphe-
nous artery was monitored to record distal pressure of
collateral arteries.
Adenosine triphosphate disodium (ATP, Kowa Shinyaku
Co, Tokyo, Japan) was continuously infused into the pump-
driven circuit (1 mg/kg/min) to achieve maximum vaso-
dilation of the hind limb, and the shunt system was driven
to perfuse blood at two different proximal pressure levels
between 45 and 70mmHg. At each pressure level, 15-m-
diameter colored microspheres (Dye-Trak, Triton Tech-
nology Inc, San Diego, Calif) with different colors (eosin
and yellow) were injected into the shunt circuit, and a
reference blood sample was withdrawn for 3 minutes at a
rate of 0.6 mL/min.
After these procedures, the distal half of the whole
thighmuscles and whole crural muscles were dissected. The
number of microspheres accumulated in the dissected mus-cles was counted according to the supplier’s manual, and
muscle blood flow (BF) was calculated as described previ-
ously.10 Collateral conductance was calculated as [100 
BF/(PP–DP)], where PP is the proximal pressure andDP is
the distal pressure, and the mean values under different
pressures were used for statistical analysis.
Histologic study. To evaluate capillary formation in
the ischemic muscle, the capillary/muscle fiber ratio was
measured (capillary density).10 The animals were eutha-
nized after the above evaluations, and two muscle speci-
mens were obtained from themedial side of the central part of
the left semimembranous muscle of each animal. Frozen
5-m transverse sections were cut from two specimens, and
capillary endothelial cells were stained by the indoxy-
tetrazolium method. A total of 20 different fields from the
two muscle sections were randomly selected, and capillaries
were counted to determine the capillary density, as de-
scribed previously.7
Statistical analysis. Counting for determination of
the angiographic score and capillary density was performed
by a student helper in a blinded fashion. Results are ex-
pressed as mean  standard deviation. Comparisons be-
tween two values were performed using an unpaired t test.
All data were considered significant at P  .05.
RESULTS
In vitro study. Western blot analysis showed expression
of ephrin-B2 in the lysate of AxCAmephrinB2-treated rabbit
fibroblasts at 43 kD. Abundant expression of ephrin-B2 was
observed at 3, 7, and 14 days after infection, and the expres-
sion decreased after day 21 (Fig 1, A). Western blot analysis
also revealed that Eph-B4 was expressed in AxCAmEphB4-
treated fibroblasts at about 130 kD (Fig 1, B).
In the mixture of AxCAmephrinB2-treated fibroblasts
and AxCAmEphB4-treated cells, obvious and considerable
aggregation of the cells was observed after 30 minutes of
agitation (Fig 1, C). However, no aggregation was formed
in the mixture of cweAxCAmephrinB2-treated cells and
AxCALacZ-treated cells.
Calf blood pressure ratio. Immediately after the left
femoral artery was removed, the Doppler probe could
detect no sound of blood flow in the left calf. The calf blood
pressure ratio (left calf systolic pressure/right calf systolic
pressure) showed no significant difference between the
control and ephrin groups immediately after femoral artery
removal and before cell administration. At 28 days after
injection of infected fibroblasts, the calf blood pressure
ratio in the ephrin group was significantly higher than that
in the control group (Fig 2).
Angiographic score. Selective internal iliac arterio-
grams showed few collateral vessels in the control group at
28 days after cell injection (Fig 3, A), whereas marked
development of collateral vessels was detected in the ephrin
group (Fig 3, B). The angiographic score, which was used
to quantify collateral development in the thigh muscles,
was significantly higher in the ephrin group than in the
control group (Fig 3, C).
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vivo blood flow at 28 days after cell injection, spasm of the
left internal iliac artery occurred in one animal of the
control group, which was due to a problem with catheter
manipulation. Because a proper measurement was not
available, the data of this animal were omitted. Other
measurement data of blood flow at rest showed a significant
increase in the ephrin group compared with the control
group (Fig 4, A). Maximum blood flow after injection of
papaverine was also greater in the ephrin group than in the
control group (Fig 4, A).
Collateral conductance. To determine the function of
developed collateral vessels, collateral conductance was mea-
sured at 28 days after cell administration. Because of the
complicated procedure and strong vasodilator effect of ATP,
Fig 1. A, Western blot analysis showed in vitro expression of
ephrin-B2 on AxCAmephrinB2-treated rabbit fibroblasts. Eph-
rin-B2 was detected at 43 kD. B, Western blot analysis of Eph-B4
showed in vitro expression of Eph-B4 (about 130 kD) on Ax-
CAmEphB4-treated fibroblasts.C, Photographs showed amixture
of (left panel) AxCAmephrinB2-treated fibroblasts and Ax-
CAmEphB4-treated fibroblasts and (right panel) a mixture of
AxCAmephrinB2-treated fibroblasts and AxCALacZ-treated fi-
broblasts. Obvious aggregation of cells is observed in the left panel,
but no aggregation is observed in the right panel. C, Control
sample (lysate of cells not infected); d, days after infection.proper blood flow with stable pressure was successfullyachieved in only 15 animals (ephrin group, 7; control group,
8). The data of collateral conductance in the ephrin group
were significantly improved compared with the control group
(Fig 4, B).
Histologic analysis. In the ephrin group, capillary
density of the left semimembranous muscle on day 28 was
significantly higher than that in the control group (Fig 5).
Neither muscle necrosis nor degradation was observed on
histologic examination.
DISCUSSION
The ephrin ligand and its receptor, Eph, were initially
reported as having functions in the nervous system.23 Ephrin
is a membrane-bound ligand and is categorized into two
classes based on binding specificity for the plasma mem-
brane.24,25 Ephrin-A is attached to the surface of the plasma
membrane through a glycosyl phosphoinositide anchor, and
ephrin-B is a transmembrane ligand. The Eph receptor is also
classified into two subfamilies by structural homology; the
Eph-A subfamily mainly binds to ephrin-A, and the Eph-B
subfamily to ephrin-B. To activate Eph receptors, ephrin li-
gands require membrane attachment or clustering, and
ephrins in a soluble form would not be able to function.26
A variety of studies have revealed the multifunctional
nature of the ephrin–Eph system, and Wang et al13 first
demonstrated important roles of ephrin–Eph in vascular
development. In their study, targeted disruption of the
gene expressing ephrin-B2 resulted in embryonic lethality
due to a defect in arterial and venous remodeling of the
capillary bed. Eph-B4 gene knockout animals further dis-
played a symmetric phenotype to that of ephrin-B2mutants
in the cardiovascular system, indicating reciprocal interac-
tion of ephrin-B2 and Eph-B4 in vascular development.
Meanwhile, recent studies showed that ephrin-B2 also
Fig 2. Calf blood pressure ratio (ratio of left calf systolic pressure
to right calf systolic pressure) was measured immediately after
femoral artery removal (flow was not detected) and immediately
before cell administration in control group (open circles, n 12) vs
ephrin group (filled circles, n  10), and 28 days after cell admin-
istration. Mean values are shown with the standard deviation
(range bars). *P  .0001. NS, No significant difference. P 
.0855.played some roles in angiogenic reactions in adults.14,16,17,27
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endothelium of tumor vasculature and the female reproduc-
tive system. The same study further demonstrated that
ephrin-B2 expression progressively extended from the endo-
Fig 3. A, Selective internal iliac angiograms from animals in
control group and (B) ephrin group at 28 days after cell adminis-
tration. C, Development of collateral vessels was quantified by
angiographic score in the control group (white bar, n 12) vs the
ephrin group (filled bar, n 10). Mean values are shown with the
standard deviation (range bars). *P  .0006.thelium to surrounding smooth muscle cells and pericytes.These findings suggest that ephrin-B2 participates not only in
angiogenesis but also in arteriogenesis in the adult.
In the present study, we transferred the mouse ephrin-B2
gene to rabbit fibroblasts and then injected ephrin-B2–
expressing fibroblasts into a possible donor artery of the isch-
emic lesion. To confirm that the transfected ephrin-B2 gene
was expressed in the rabbit fibroblasts,Western blot analysis of
ephrin-B2 was done on lysates of AxCAmephrinB2-treated
rabbit fibroblasts, and abundant expression of ephrin-B2 was
observed for14 days after infection.
Our previous study showed that autofibroblasts gene-
transduced with an adenovirus vector (first generation) in
the same manner were eliminated from the host by 14 days
after injection.7 Thus, the duration of ephrin-B2 expression
was considered to be sufficient with this delivery system
because gene transfer was done at 48 hours before cell
administration. We also mixed AxCAmephrinB2-treated
rabbit fibroblasts with AxCAmEphB4-treated fibroblasts
under in vitro conditions. A mixture of these cells exhibited
cell aggregation after 30 minutes of agitated incubation,
showing that the ephrin-B2 ligand was present on the
membrane surface of AxCAmephrinB2-treated fibroblasts
and was able to adhere to its receptor. Because injection of
5 106 fibroblasts into the donor artery has been shown to
achieve an appropriate distribution of cells in the peripheral
vascular network of the artery,7,9 ephrin-B2–expressing
Fig 4. A, In vivo blood flow of left internal iliac artery was
measured with a Doppler guidewire. Average peak velocity was
recorded at rest in the control group (white bar, n 11) and ephrin
group (filled bar, n  10), maximum average peak velocity was
measured after papaverine injection, and blood flow was calcu-
lated. B, Collateral conductance representing the function of
developed collateral vessels in the control group and ephrin group.
Mean values are presented with the standard deviation (range
bars). *P  .0014; **P  .0007; ***P  .0097.fibroblasts might be successfully delivered to the peripheral
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study, andmembrane-bound ephrin-B2might interact with
Eph receptors on vascular cells.
The aim of the present study was to determine whether
delivery of ephrin-B2–expressing fibroblasts to peripheral
sites of the donor artery could lead to the development of
functional collateral vessels to improve blood perfusion in
Fig 5. A, Alkaline phosphatase staining of ischemic hind limb mus-
cle in control group and (B) ephrin group. Panels A and B
magnification  400. C, Capillary density of left semimembranous
muscle wasmeasured in tissue sections stained by indoxyl-tetrazolium
method in control group (white bar, n 12) and ephrin group (filled
bar,n10).Mean values are presentedwith the standard deviation
(range bars). P  .0003.ischemic tissue. Although all evaluation methods in thisstudy have been frequently used and established in previous
studies of angiogenic therapy,1 each evaluation method
has a specific property to evaluate angiogenic reactions. It is
known that three processes contribute to angiogenic reac-
tions in vivo: vasculogenesis, angiogenesis, and arteriogen-
esis.15,28
The calf blood pressure ratio and in vivo blood flow are
conventional parameters indicating the general degree of
collateral development. Capillary density of ischemic mus-
cle reflects vasculogenesis and angiogenesis because they
are processes of capillary formation from endothelial cells or
endothelial progenitor cells. On the other hand, the angio-
graphic score represents the number of arteries with a
relatively large diameter because angiograms provide im-
ages of vessels of 50 m in diameter.29 Collateral con-
ductance is a parameter of collateral vessel function to
conduct blood flow.10,22,29 Superior function as a blood
flow conduit requires a certain luminal diameter and mat-
uration of wall structure.5 Thus, these two evaluations
show the degree of vessel maturation and enlargement that
are acquired through the process of arteriogenesis.10
In the present study, the results of all evaluations revealed
significant improvement in the ephrin group compared with
the control group, suggesting that delivery of ephrin-B2 en-
hanced several angiogenic reactions involving arteriogenesis
and contributed to the formation of functional collateral ves-
sels. As a parameter of arteriogenesis, immunostaining for
smooth muscle actin of muscle specimens is also helpful, al-
though this staining reflects only vessel maturation, not luminal
diameter.10 Previous studies thus far have presented little evi-
dence that ephrin-B2 induces arteriogenesis in the adult vascula-
ture.Onepossible reason for thescarceevidence is thatdeliveryof
a membrane-bound ligand is relatively difficult in vivo. Presum-
ably, ex vivo gene transfermight be an appropriatemethod for in
vivo delivery of membrane-bound ligands such as ephrin-B2
because cells are used as the delivery target.
Although ex vivo delivery of ephrin-B2 significantly
induced therapeutic neovascularization in ischemic limbs,
there are some issues that the present study did not resolve.
One is the mechanism of angiogenic reactions induced by
ephrin-B2. It is known that ephrin-B2 and its reciprocal
receptor Eph-B4 are expressed on the arterial endothelium
and venous endothelium, respectively, and previous studies
demonstrated that the repulsive interaction of ephrin-B2
and Eph-B4 regulated the development of arteries and veins
in the embryo.13,15,24 In adults, studies using ephrin-B2/Fc
chimeric protein have shown that ephrin-B2/Fc stimulated
migration and proliferation of human endothelial cells
through the phosphatidylinositol 3-kinase/Akt pathway,
although the details of the angiogenic mechanisms of the
ephrin–Eph interaction remain unclear.28,30
Another issue is the time course of the therapeutic
effects. In the present study, we evaluated the efficacy of
ephrin-B2 treatment only at 28 days after cell administra-
tion. However, it is possible that more favorable data would
be detected at other time points after cell injection. To
clarify the therapeutic properties and clinical relevance of
the present therapy relative to other angiogenic therapies, it
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angiogenic reactions induced by ephrin–Eph. Further, ex
vivo delivery of Eph-B4, which could be performed in a
similar fashion to that in the present study, might provide
strong clues for understanding the angiogenic mechanisms
of the ephrin–Eph interaction.
CONCLUSION
We delivered the gene expressing ephrin-B2 to the rabbit
ischemic hind limb by using an ex vivo method of gene
transfer and demonstrated significant development of collat-
eral vessels and improvement of tissue perfusion 28 days later.
The results of the angiographic score and collateral conduc-
tance revealed that the developed collateral vessels had a
relatively large size and mature structure. These findings sug-
gest that ephrin-B2 potentially promotes arteriogenesis as well
as capillary formation in the adult vasculature.
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